Search
4'-Methylene-5,8,10-trideazaaminopterin
go.drugbank.com/drugs/DB05616InvestigationalCH-1504 is a an antirheumatic agent that has been shown in vitro to be a nonpolyglutamylatable and nonhydroxylatable antifolate that is more efficiently taken up into cells by the reduced folate carrier
International brands: M-Trexbeta-Alanine
go.drugbank.com/drugs/DB03107InvestigationalA rare genetic disorder, hyper-beta-alaninemia, has been reported. … beta-Alanine is an amino acid formed in vivo by the degradation of [dihydrouracil] and [carnosine].
beta-Hydroxybutyric acid
go.drugbank.com/drugs/DB16506InvestigationalBeta-hydroxybutyrate is being studied in around 230 clinical trials, including NCT06351124 (recruiting for Crohn's disease), NCT05584371 (recruiting for safety and tolerability of exogenous ketosis), NCT04656236 (completed for type 1 dia...
EGEN-001
go.drugbank.com/drugs/DB05953InvestigationalEGEN-001 is a novel non-viral vector consisting of a plasmid DNA encoding the human gene for interleukin 12 (IL-12) and a biocompatible, biodegradable delivery polymer with potential antineoplastic activity
Tezacitabine
go.drugbank.com/drugs/DB06433InvestigationalA synthetic purine nucleoside analogue with potential antineoplastic activity.
CR002
go.drugbank.com/drugs/DB05139InvestigationalCR002 is a novel investigational fully human monoclonal antibody that blocks the activity of excess platelet-derived growth factor-D (PDGF-D), a target shown to play a role in kidney inflammation. … This is a novel therapeutic approach to treat kidney inflammation.
SBT-100
go.drugbank.com/drugs/DB17215ExperimentalSBT-100 is an anti-signal transducer and activator of transcription 3 (STAT3) B VHH13 single-domain antibody (sdAb).
RAV12
go.drugbank.com/drugs/DB05140InvestigationalRAV12 is a solid. RAV12 is a chimeric antibody that recognizes RAAG12, an N-linked carbohydrate antigen found on gastric, colon, pancreatic, prostate, ovarian, breast, and kidney cancer cells.
AVX-001
go.drugbank.com/drugs/DB19194Investigationalinvestigation in clinical trial NCT05164393 (Phase I/iia Trial to Evaluate AVX001 Gel in Doses of 1% or 3% Compared With Vehicle Over Four Weeks of Field-directed Treatment Period in Adult Subjects With AK